Sigyn Therapeutics, Inc. (SIGY)
USD 3.15
(0.0%)
USD 3.15
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 2.39 Million USD | 27.72% |
| 2022 | 1.87 Million USD | 101.01% |
| 2021 | 933.91 Thousand USD | 80.06% |
| 2020 | 518.66 Thousand USD | -72.7% |
| 2019 | 1.89 Million USD | 3.51% |
| 2018 | 1.83 Million USD | 49.01% |
| 2017 | 1.23 Million USD | 98.84% |
| 2016 | 619.42 Thousand USD | 4819.55% |
| 2015 | 12.59 Thousand USD | 0.0% |
| 2014 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 1.93 Million USD | -26.84% |
| 2024 Q1 | 2.64 Million USD | 10.52% |
| 2023 Q2 | 2.84 Million USD | 5.42% |
| 2023 Q4 | 2.39 Million USD | -23.86% |
| 2023 FY | 2.39 Million USD | 27.72% |
| 2023 Q3 | 3.14 Million USD | 10.68% |
| 2023 Q1 | 2.69 Million USD | 43.78% |
| 2022 Q3 | 1.76 Million USD | 46.15% |
| 2022 Q4 | 1.87 Million USD | 6.17% |
| 2022 Q2 | 1.2 Million USD | 23.35% |
| 2022 Q1 | 980.84 Thousand USD | 5.03% |
| 2022 FY | 1.87 Million USD | 101.01% |
| 2021 Q2 | 908.59 Thousand USD | 57.13% |
| 2021 Q4 | 933.91 Thousand USD | -4.32% |
| 2021 FY | 933.91 Thousand USD | 80.06% |
| 2021 Q1 | 578.25 Thousand USD | 11.49% |
| 2021 Q3 | 976.07 Thousand USD | 7.43% |
| 2020 Q4 | 518.66 Thousand USD | -73.47% |
| 2020 Q2 | 1.89 Million USD | 0.0% |
| 2020 Q1 | 1.89 Million USD | -0.26% |
| 2020 FY | 518.66 Thousand USD | -72.7% |
| 2020 Q3 | 1.95 Million USD | 3.17% |
| 2019 Q4 | 1.89 Million USD | 1.61% |
| 2019 FY | 1.89 Million USD | 3.51% |
| 2019 Q3 | 1.86 Million USD | 2.71% |
| 2019 Q2 | 1.82 Million USD | 0.51% |
| 2019 Q1 | 1.81 Million USD | -1.31% |
| 2018 Q4 | 1.83 Million USD | 1.97% |
| 2018 Q3 | 1.79 Million USD | 4.49% |
| 2018 Q2 | 1.72 Million USD | 5.36% |
| 2018 Q1 | 1.63 Million USD | 32.73% |
| 2018 FY | 1.83 Million USD | 49.01% |
| 2017 Q4 | 1.23 Million USD | 4.01% |
| 2017 Q1 | 807.74 Thousand USD | 30.4% |
| 2017 FY | 1.23 Million USD | 98.84% |
| 2017 Q2 | 1.16 Million USD | 44.54% |
| 2017 Q3 | 1.18 Million USD | 1.42% |
| 2016 Q2 | 299.04 Thousand USD | 91.92% |
| 2016 Q3 | 443.84 Thousand USD | 48.42% |
| 2016 Q1 | 155.81 Thousand USD | 1137.53% |
| 2016 FY | 619.42 Thousand USD | 4819.55% |
| 2016 Q4 | 619.42 Thousand USD | 39.56% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q4 | 12.59 Thousand USD | 0.0% |
| 2015 FY | 12.59 Thousand USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 94.181% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 41.83% |
| SQZ Biotechnologies Company | 27.47 Million USD | 91.272% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 94.472% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 91.945% |
| Mesoblast Limited | 118.7 Million USD | 97.98% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -152.852% |
| Genus plc | 233.1 Million USD | 98.971% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | 18.177% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -78.457% |
| Marizyme, Inc. | 18.71 Million USD | 87.19% |
| ContraFect Corporation | 2.88 Million USD | 16.775% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -219.697% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -1669.708% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -65.781% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -3.086% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 57.625% |
| MultiCell Technologies, Inc. | 202.58 USD | -1183493.642% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 95.829% |
| EV Biologics, Inc. | 1.49 Million USD | -60.41% |
| Q BioMed Inc. | 4.1 Million USD | 41.661% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 92.756% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -280.545% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -95.197% |
| Biomind Labs Inc. | 735.54 Thousand USD | -225.981% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 98.602% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 81.552% |
| Skye Bioscience, Inc. | 4.61 Million USD | 48.048% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -169.995% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -1594.289% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 59.16% |
| IMV Inc. | 28.88 Million USD | 91.699% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -9222.773% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -6.17% |
| GB Sciences, Inc. | 1.75 Million USD | -36.288% |
| Alpha Cognition Inc. | 1.22 Million USD | -96.475% |
| HST Global, Inc. | 98.31 Thousand USD | -2338.719% |
| CSL Limited | 12.18 Billion USD | 99.98% |
| Halberd Corporation | 150 Thousand USD | -1498.483% |
| Enzolytics Inc. | 996.33 Thousand USD | -140.654% |
| Resverlogix Corp. | 6.49 Million USD | 63.061% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -402.141% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -838.106% |
| argenx SE | 20 Million USD | 88.011% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 94.737% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 11.481% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -23349.623% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.426% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -1095.181% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -945.712% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 96.455% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 20.768% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -566.571% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 88.205% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -1512.956% |
| BioStem Technologies, Inc. | 4.71 Million USD | 49.108% |
| ONE Bio Corp. | 19.71 Million USD | 87.838% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -858.392% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -864.025% |
| Agentix Corp. | 50 Thousand USD | -4695.448% |
| LadRx Corporation | 33.6 Thousand USD | -7034.809% |
| Cell Source, Inc. | 9.25 Million USD | 74.09% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -217.074% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -217.074% |
| NovAccess Global Inc. | 2.19 Million USD | -8.993% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 66.099% |
| Itoco Inc. | 228.37 Thousand USD | -949.897% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -1036.497% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 51.882% |
| Kadimastem Ltd | 891.22 Thousand USD | -169.037% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -496.673% |
| CytoDyn Inc. | 30.07 Million USD | 92.028% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -395.107% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -581.468% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 69.338% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -1857.326% |
| Rebus Holdings, Inc. | 310 Thousand USD | -673.459% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 49.365% |
| International Stem Cell Corporation | 4.17 Million USD | 42.611% |
| Bioxytran, Inc. | 1.92 Million USD | -24.557% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -3741.706% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -9.942% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 71.167% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 72.071% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -54.147% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -794.673% |
| Neutra Corp. | 54.15 Thousand USD | -4327.439% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -31.023% |
| PureTech Health plc | 25.51 Million USD | 90.602% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -95.856% |
| IXICO plc | 472.02 Thousand USD | -407.968% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 84.532% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 96.149% |
| CSL Limited | 12.18 Billion USD | 99.98% |
| Cellectis S.A. | 92.77 Million USD | 97.416% |